News Celyad Oncology SA BOERSE MUENCHEN

Equities

1C0S

US1512052002

Real-time BOERSE MUENCHEN Other stock markets			5-day change	1st Jan Change
- ^EUR	-.--%		+10.27%	-.--%

04-04	Celyad Oncology SA Reports Earnings Results for the Full Year Ended December 31, 2023	CI
02-09	Celyad Oncology Seeks Termination of Reporting Obligations to US SEC	MT

Summary

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Celyad Oncology reports full year 2023 financial results and recent business highlights	04-05	AQ
Celyad Oncology : Report of the Statutory Auditor on the Consolidated Annual Account 2023 ENG	04-05	PU
Celyad Oncology SA Reports Earnings Results for the Full Year Ended December 31, 2023	04-04	CI
Celyad Oncology Seeks Termination of Reporting Obligations to US SEC	02-09	MT
Celyad Oncology provides fourth quarter 2023 business update and 2024 outlook	01-16	AQ
Publication of a transparency notification received from Fortress Investment Group LLC (Article 14 §1 of the Law of 2 May 2007)	12-20	AQ
Celyad Oncology CEO Resigns	12-05	MT
Celyad Oncology CEO Steps Down for Personal Reasons	12-04	MT
Celyad announces management change	12-04	AQ
Celyad Oncology SA Announces Executive Change	12-04	CI
Celyad Oncology Sa Announces Executive Change	12-04	CI
Celyad Oncology : announces management change	12-01	PU
Celyad Oncology : reports third quarter 2023 financial results and recent business highlights - Form 6-K	11-24	PU
Celyad Oncology SA - Publication of a transparency notification received from Fortress Investment Group LLC	11-22	AQ
Publication of a transparency notification received from Fortress Investment Group LLC (Article 14 §1 of the Law of 2 May 2007)	11-21	AQ
Celyad Oncology : CONVENING LETTER TO THE EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS OF 22 DECEMBER 2023 - Form 6-K	11-21	PU
Celyad Oncology SA announced that it has received ?9.794 million in funding from CFIP CLYD (UK) Limited, Fortress Investment Group LLC, Tolefi S.A.	11-13	CI
Celyad Oncology reports third quarter 2023 financial results and recent business highlights	11-09	AQ
Celyad Oncology : CONVENING LETTER TO THE EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS OF 14 NOVEMBER 2023 - Form 6-K	23-10-27	PU
Celyad Oncology to Cancel American Depository Receipt Program in October	23-09-26	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Celyad Oncology SA BOERSE MUENCHEN

Equities

1C0S

US1512052002

Summary

Filters